Johnson & Johnson JNJ update Oct. 14th, 2026
WKN: 853260 / ISIN: US4781601046
This is not a recommendation or proposal to do anything. The data written in this article is not guaranteed. It is my private personal opinion. I`m not independent as I own a position of JnJ shares.
Johnson & Johnson is a US based company of the health sector with sales of nearly 100 bn$/yr. A bit more than half of it from the US domestic business and the remainder from international business. Its business segments are Pharmaceutical and Medical Devices. It is one of the most stable company`s of the world.
Opportunities and Risks
JnJ is a slow growing (on a stable price base) but usually very profitable business.
The general challenges for drug makers are...
- Many countries like the Europeans regulate the prices of drugs and thus limit the profits of the drug makers. The USA is no longer willing to pay R&D and development costs for the Europeans and Asians.
- Other countries as India often break the patents if the drugs seem too expensive.
- The duration of patents is limited
- It is to fear that the USA will regulate drug prices following the European example
JnJ is still one of the most stable companies of the world. The dividend is increased to 1.34 USD/share in Q2/2026. On the other hand there is no significant growth perspective. The PE of 27 (price 240$, 9$ profit est. 2026) is expensive for a stagnating business.
Observations
The biggest and most profitable segment of JnJ is the pharmaceutical business. It can be evaluated as pharmaceutical company.
JnJ generates more than half of its revenues and perhaps a bigger share of ist profits in the USA.
JnJ business is very well distributed over the world with a focus on the USA. Its business – pharmaceutical - is even in a "crazy economy" environment in its key markets less affected than other businesses. This provides stability.
Some Numbers
The revenue loss in 2023 -2024 was caused by the Spin-Off of its consumer product business Kenvue.
Major Shareholders (marketscreener (4) Jan 2026
Name %
Vanguard Group, Inc. (Subfiler) 9.821 %
Black Rock Advisors LLC 6.4%
STATE STREET CORPORATION 5,49 %
JPMorgan Investment Management, Inc. 2.437 %
Geode Capital Management LLC 2,23 %
The usual big institutional investors.
Holdings
Some News
2021/03/02 J&J to record $610M impairment charge from terminating development of therapy in Q4/2021 (4)
2021/04/13 The CDC in the USA recommended to pause the use of JnJ’s COVID-19 shot. The decision was taken after six vaccine recipients in the U.S. developed a rare disorder involving blood clots within two weeks of the inoculation (3). The corona vaccine is in the worst case only a small part of the JnJ business. As the covid-19 virus and its mutations will accompany us for decades or centuries and will most probably require annual modifications of vaccines similar to influenza vaccine. There is still plenty of potential for the future if people and politicians stay with their panic.
From a more logical point of view vaccination always bear risks. Thus it make sense for dangerous diseases only. In case of covid-19 the risk of vaccination outpaces the benefit for most people under 70years. The better question is when poeple and politicians calm down from their covid-19 hype. Then other products from JnJ will prosper.
2021/02/10 South Africa to discontinue AstraZeneca vaccine, will give J&J shots. The one-shot J&J vaccine is still being tested internationally and has not been approved in any country. But Mkhize declared that the vaccine is safe, relying on tests of 44,000 people done in South Africa, the U.S. and Latin America (2)
2020/03/16
Old Stuff
The 2024 numbers are not comparable with the 2023 data due to the spin-off of the consumer business.
JnJ spun-off its consumer business as Kenvue Inc. in Q3/2023. The JnJ shareholders were offered 8.0549 shares of Kenvue common stock per share of Johnson & Johnson common stock shares.
The covid panic faded away. Vaccine mandates were rescinded. JnJ covid revenues became negligible in 2023. JnJ strength is its widespread portfolio of medical and pharmaceutical products that benefit from the aging global population.
Some References
(4) 2020 Feb, 03 https://seekingalpha.com/news/3795276-johnson-johnson-to-record-610m-impairment-charge-from-terminating-development-of-therapy?app=1&mail_subject=pre-market-summary-on-your-portfolio-portfolio-1&utm_campaign=nl-portfolio&utm_content=link-3&utm_medium=email&utm_source=seeking_alpha
(3) 2021 April 13th https://seekingalpha.com/news/3681245-jnj-is-down-after-cdc-halts-the-use-of-its-covid-19-vaccine?mail_subject=jnj-jnj-is-down-after-cdc-halts-the-use-of-its-covid-19-vaccine&utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha
(2) 2021 Feb. 10th https://seekingalpha.com/news/3660358-south-africa-to-discontinue-astrazeneca-vaccine-will-give-jj-shots?mail_subject=jnj-south-africa-to-discontinue-astrazeneca-vaccine-will-give-j-j-shots&utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha